Single Circulating Fetal Trophoblastic Cells Eligible for Non Invasive Prenatal Diagnosis: the Exception Rather than the Rule.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 06 2020
Historique:
received: 28 01 2020
accepted: 20 05 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 15 12 2020
Statut: epublish

Résumé

Non-Invasive Prenatal Diagnosis (NIPD), based on the analysis of circulating cell-free fetal DNA (cff-DNA), is successfully implemented for an increasing number of monogenic diseases. However, technical issues related to cff-DNA characteristics remain, and not all mutations can be screened with this method, particularly triplet expansion mutations that frequently concern prenatal diagnosis requests. The objective of this study was to develop an approach to isolate and analyze Circulating Trophoblastic Fetal Cells (CFTCs) for NIPD of monogenic diseases caused by triplet repeat expansion or point mutations. We developed a method for CFTC isolation based on DEPArray sorting and used Huntington's disease as the clinical model for CFTC-based NIPD. Then, we investigated whether CFTC isolation and Whole Genome Amplification (WGA) could be used for NIPD in couples at risk of transmitting different monogenic diseases. Our data show that the allele drop-out rate was 3-fold higher in CFTCs than in maternal cells processed in the same way. Moreover, we give new insights into CFTCs by compiling data obtained by extensive molecular testing by microsatellite multiplex PCR genotyping and by WGA followed by mini-exome sequencing. CFTCs appear to be often characterized by a random state of genomic degradation.

Identifiants

pubmed: 32555262
doi: 10.1038/s41598-020-66923-9
pii: 10.1038/s41598-020-66923-9
pmc: PMC7300110
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9861

Références

Drury, S., Hill, M. & Chitty, L. S. Cell-Free Fetal DNA Testing for Prenatal Diagnosis. In Advances in Clinical Chemistry 76, 1–35 (Elsevier Inc., 2016).
Hui, L. Noninvasive Approaches to Prenatal Diagnosis: Historical Perspective and Future Directions. Methods Mol. Biol. 1885, 45–58 (2019).
doi: 10.1007/978-1-4939-8889-1_3
Mellis, R., Chandler, N. & Chitty, L. S. Next-generation sequencing and the impact on prenatal diagnosis. Expert Rev. Mol. Diagn. 18, 689–699 (2018).
doi: 10.1080/14737159.2018.1493924
Mujezinovic, F. & Alfirevic, Z. Procedure-Related Complications of Amniocentesis and Chorionic Villous. Obstet. Gynecol. 110, 687–694 (2007).
doi: 10.1097/01.AOG.0000278820.54029.e3
Hayward, J. & Chitty, L. S. Beyond screening for chromosomal abnormalities: Advances in non-invasive diagnosis of single gene disorders and fetal exome sequencing. Semin. Fetal Neonatal Med. 23, 94–101 (2018).
doi: 10.1016/j.siny.2017.12.002
Mouawia, H. et al. Circulating trophoblastic cells provide genetic diagnosis in 63 fetuses at risk for cystic fibrosis or spinal muscular atrophy. Reprod. Biomed. Online 25, 508–520 (2012).
doi: 10.1016/j.rbmo.2012.08.002
Schlütter, J. M. et al. The Number of Endovascular Trophoblasts in Maternal Blood Increases Overnight and after Physical Activity: An Experimental Study. Fetal Diagn. Ther. 40, 54–8 (2016).
doi: 10.1159/000441294
Beaudet, A. L. Using fetal cells for prenatal diagnosis: History and recent progress. Am. J. Med. Genet. C. Semin. Med. Genet. 172, 123–7 (2016).
doi: 10.1002/ajmg.c.31487
Hvichia, G. E. et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int. J. cancer 138, 2894–904 (2016).
doi: 10.1002/ijc.30007
Pantel, K. & Alix-Panabières, C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat. Rev. Clin. Oncol. 16, 409–424 (2019).
doi: 10.1038/s41571-019-0187-3
Illumina website. Available at, https://emea.illumina.com/ (Accessed: 3rd September 2019).
Moutou, C., Gardes, N. & Viville, S. New tools for preimplantation genetic diagnosis of Huntington’s disease and their clinical applications. Eur. J. Hum. Genet. 12, 1007–14 (2004).
doi: 10.1038/sj.ejhg.5201291
Van Rij, M. C. et al. Preimplantation genetic diagnosis (PGD) for Huntington’s disease: the experience of three European centres. Eur. J. Hum. Genet. 20, 368–75 (2012).
doi: 10.1038/ejhg.2011.202
Marelli, C. et al. Mini-Exome Coupled to Read-Depth Based Copy Number Variation Analysis in Patients with Inherited Ataxias. Hum. Mutat. 37, 1340–1353 (2016).
doi: 10.1002/humu.23063
Fujita, A., Uchida, N., Haro-Mora, J. J., Winkler, T. & Tisdale, J. β-Globin-Expressing Definitive Erythroid Progenitor Cells Generated from Embryonic and Induced Pluripotent Stem Cell-Derived Sacs. Stem Cells 34, 1541–1552 (2016).
doi: 10.1002/stem.2335
Kølvraa, S., Christensen, B., Lykke-Hansen, L. & Philip, J. The fetal erythroblast is not the optimal target for non-invasive prenatal diagnosis: preliminary results. J. Histochem. Cytochem. 53, 331–6 (2005).
doi: 10.1369/jhc.4A6396.2005
Mouawia, H. et al. Circulating trophoblastic cells provide genetic diagnosis in 63 fetuses at risk for cystic fibrosis or spinal muscular atrophy. 508–520 (2012).
Best, S. et al. Promises, pitfalls and practicalities of prenatal whole exome sequencing. Prenat. Diagn. 38, 10–19 (2018).
doi: 10.1002/pd.5102
Wachtel, S. et al. Fetal cells in the maternal circulation: isolation by multiparameter flow cytometry and confirmation by polymerase chain reaction. Hum. Reprod. 6, 1466–9 (1991).
doi: 10.1093/oxfordjournals.humrep.a137290
Wachtel, S. S. et al. Fetal cells in maternal blood: recovery by charge flow separation. Hum. Genet. 98, 162–6 (1996).
doi: 10.1007/s004390050181
de Graaf, I. M. et al. Enrichment, identification and analysis of fetal cells from maternal blood: evaluation of a prenatal diagnosis system. Prenat. Diagn. 19, 648–52 (1999).
doi: 10.1002/(SICI)1097-0223(199907)19:7<648::AID-PD600>3.0.CO;2-X
Hatt, L. et al. A new marker set that identifies fetal cells in maternal circulation with high specificity. Prenat. Diagn. 1066–1072, https://doi.org/10.1002/pd.4429 (2014).
Hou, S. et al. Imprinted NanoVelcro Microchips for Isolation and Characterization of Circulating Fetal Trophoblasts: Toward Noninvasive Prenatal Diagnostics. ACS Nano 11, 8167–8177 (2017).
doi: 10.1021/acsnano.7b03073
Lee, J. W., Shin, J.-Y. & Seo, J.-S. Identification of novel mutations in FFPE lung adenocarcinomas using DEPArray sorting technology and next-generation sequencing. J. Appl. Genet. 59, 269–277 (2018).
doi: 10.1007/s13353-018-0439-4
Smerage, J. B. et al. Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol. Oncol. 7, 680–692 (2013).
doi: 10.1016/j.molonc.2013.02.013
Kim, Y.-N., Koo, K. H., Sung, J. Y., Yun, U.-J. & Kim, H. Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis. Int. J. Cell Biol. 2012, 1–11 (2012).
doi: 10.1155/2012/306879
Simpson, C. D., Anyiwe, K. & Schimmer, A. D. Anoikis resistance and tumor metastasis. Cancer Lett. 272, 177–85 (2008).
doi: 10.1016/j.canlet.2008.05.029
Huppertz, B. & Kingdom, J. C. P. Apoptosis in the trophoblast–role of apoptosis in placental morphogenesis. J. Soc. Gynecol. Investig. 11, 353–62 (2004).
doi: 10.1016/j.jsgi.2004.06.002
Huang, L., Ma, F., Chapman, A., Lu, S. & Xie, X. S. Single-Cell Whole-Genome Amplification and Sequencing: Methodology and Applications. Annu. Rev. Genomics Hum. Genet. 16, 79–102 (2015).
doi: 10.1146/annurev-genom-090413-025352
Vossaert, L. et al. Validation Studies for Single Circulating Trophoblast Genetic Testing as a Form of Noninvasive Prenatal Diagnosis. Am. J. Hum. Genet. 105, 1262–1273 (2019).
doi: 10.1016/j.ajhg.2019.11.004
Bianchi, D. W., Zickwolf, G. K., Weil, G. J. & Sylvester, S. & DeMaria, M. a. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc. Natl. Acad. Sci. USA 93, 705–8 (1996).
doi: 10.1073/pnas.93.2.705

Auteurs

Laure Cayrefourcq (L)

Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Center of Montpellier, Montpellier, France.

Marie-Claire Vincent (MC)

Laboratoire de Génétique de Maladies Rares, Institut Universitaire de Recherche Clinique, EA7402 Université de Montpellier, CHU Montpellier, Montpellier, France.

Sandra Pierredon (S)

Laboratoire de Génétique de Maladies Rares, Institut Universitaire de Recherche Clinique, EA7402 Université de Montpellier, CHU Montpellier, Montpellier, France.

Céline Moutou (C)

Laboratoire de Diagnostic Préimplantatoire, Hôpitaux Universitaires de Strasbourg, site du CMCO, Strasbourg, France.

Marion Imbert-Bouteille (M)

Laboratoire de Génétique de Maladies Rares, Institut Universitaire de Recherche Clinique, EA7402 Université de Montpellier, CHU Montpellier, Montpellier, France.

Emmanuelle Haquet (E)

Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Université de Montpellier, CHU de Montpellier, Montpellier, France.

Jacques Puechberty (J)

Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Université de Montpellier, CHU de Montpellier, Montpellier, France.

Marjolaine Willems (M)

Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Université de Montpellier, CHU de Montpellier, Montpellier, France.

Cathy Liautard-Haag (C)

Laboratoire de Génétique de Maladies Rares, Institut Universitaire de Recherche Clinique, EA7402 Université de Montpellier, CHU Montpellier, Montpellier, France.

Nicolas Molinari (N)

DIM, CHU Montpellier - Hôpital la Colombière, Montpellier, France.

Cécile Zordan (C)

Service de Génétique Médicale, Groupe Hospitalier Pellegrin, CHU de Bordeaux, Bordeaux, France.

Virginie Dorian (V)

Service de Génétique Médicale, Groupe Hospitalier Pellegrin, CHU de Bordeaux, Bordeaux, France.

Caroline Rooryck-Thambo (C)

Service de Génétique Médicale, Groupe Hospitalier Pellegrin, CHU de Bordeaux, Bordeaux, France.

Cyril Goizet (C)

Service de Génétique Médicale, Groupe Hospitalier Pellegrin, CHU de Bordeaux, Bordeaux, France.

Annabelle Chaussenot (A)

Service de Génétique Médicale, Centre de Référence des Maladies Mitochondriales, Hôpital de l'Archet 2, Nice, France.

Cécile Rouzier (C)

Service de Génétique Médicale, Centre de Référence des Maladies Mitochondriales, Hôpital de l'Archet 2, Nice, France.

Amandine Boureau-Wirth (A)

Service de Génétique Médicale, Centre de Référence des Maladies Mitochondriales, Hôpital de l'Archet 2, Nice, France.

Laetitia Monteil (L)

Service de Génétique Médicale, CHU de Toulouse, Toulouse, France.

Patrick Calvas (P)

Service de Génétique Médicale, CHU de Toulouse, Toulouse, France.

Claire Miry (C)

Department of Maternal Fetal Medicine, Strasbourg University Hospital, Strasbourg, France.

Romain Favre (R)

Department of Maternal Fetal Medicine, Strasbourg University Hospital, Strasbourg, France.

Yuliya Petrov (Y)

Laboratoire de Cytologie Clinique et Cytogénétique, CHU de Nîmes, Nîmes, France.

Philippe Khau Van Kien (P)

Laboratoire de Cytologie Clinique et Cytogénétique, CHU de Nîmes, Nîmes, France.

Elsa Le Boette (E)

Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France.

Mélanie Fradin (M)

Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France.

Catherine Alix-Panabières (C)

Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Center of Montpellier, Montpellier, France.

Claire Guissart (C)

Laboratoire de Génétique de Maladies Rares, Institut Universitaire de Recherche Clinique, EA7402 Université de Montpellier, CHU Montpellier, Montpellier, France. claire.guissart@inserm.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH